Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268219 | 0.93 | MAPK8 (0.52) | HTR2CMAPK8 | |
| SCHEMBL2273731 | 0.78 | HTR2C (0.47) | HTR2CL3MBTL1ADORA2ASYK | |
| SCHEMBL2271526 | 0.74 | HTR2C (0.43) | HTR2CL3MBTL1 | |
| SCHEMBL13531785 | 0.74 | HTR2C (0.47) | HTR2CL3MBTL1 | |
| SCHEMBL1934653 | 0.73 | HTR2C (0.49) | HTR2CL3MBTL1TRIM24SYK | |
| SCHEMBL6280533 | 0.72 | MAPK8 (0.50) | MAPK8SYK | |
| SCHEMBL2221438 | 0.72 | AURKA (0.60) | HTR2CSYK | |
| SCHEMBL15956956 | 0.72 | AURKA (0.50) | HTR2CSYK | |
| SCHEMBL1935507 | 0.72 | HTR2C (0.40) | HTR2CL3MBTL1 | |
| SCHEMBL103894 | 0.71 | HTR2C (0.53) | HTR2CL3MBTL1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023279938-A1 | 2,6,8-POLYSUBSTITUTED IMIDAZO[1,2-A]PYRAZINE, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 无锡市第二人民医院 | 2023-01-12 | — | — | WO | disclosed |
| CN-113480543-B | 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof | 无锡市第二人民医院 | 2022-05-17 | — | — | CN | disclosed |
| CN-113480543-A | 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof | 无锡市第二人民医院 | 2021-10-08 | — | — | CN | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | HTR2C 2214/4885MAPK8 381/4885L3MBTL1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.